HK1183612A1 - Pharmaceutical dosage form comprising 6-fluoro-(n-methyl- or n,n-dimethyl- )-4-phenyl-4,9-dihydro-3h-spiro[cylohexane-1,1-pyrano[3,4,b]indol]-4- amine 6--(n-- nn-)-4--49--3h-[-11- [34b]]-4- - Google Patents
Pharmaceutical dosage form comprising 6-fluoro-(n-methyl- or n,n-dimethyl- )-4-phenyl-4,9-dihydro-3h-spiro[cylohexane-1,1-pyrano[3,4,b]indol]-4- amine 6--(n-- nn-)-4--49--3h-[-11- [34b]]-4-Info
- Publication number
- HK1183612A1 HK1183612A1 HK13109593.7A HK13109593A HK1183612A1 HK 1183612 A1 HK1183612 A1 HK 1183612A1 HK 13109593 A HK13109593 A HK 13109593A HK 1183612 A1 HK1183612 A1 HK 1183612A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cylohexane
- pyrano
- indol
- spiro
- dihydro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37064810P | 2010-08-04 | 2010-08-04 | |
EP10008117 | 2010-08-04 | ||
PCT/EP2011/003900 WO2012016695A2 (en) | 2010-08-04 | 2011-08-04 | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1183612A1 true HK1183612A1 (en) | 2014-01-03 |
Family
ID=43382487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13109593.7A HK1183612A1 (en) | 2010-08-04 | 2013-08-16 | Pharmaceutical dosage form comprising 6-fluoro-(n-methyl- or n,n-dimethyl- )-4-phenyl-4,9-dihydro-3h-spiro[cylohexane-1,1-pyrano[3,4,b]indol]-4- amine 6--(n-- nn-)-4--49--3h-[-11- [34b]]-4- |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP2600846B1 (xx) |
JP (1) | JP6010534B2 (xx) |
KR (1) | KR101882663B1 (xx) |
CN (1) | CN103079548A (xx) |
AR (1) | AR082561A1 (xx) |
AU (1) | AU2011287952B2 (xx) |
BR (1) | BR112013002696A2 (xx) |
CA (1) | CA2804077C (xx) |
CL (1) | CL2012003583A1 (xx) |
CO (1) | CO6640317A2 (xx) |
DK (1) | DK2600846T3 (xx) |
EC (1) | ECSP13012424A (xx) |
ES (1) | ES2563735T3 (xx) |
HK (1) | HK1183612A1 (xx) |
HR (1) | HRP20151337T1 (xx) |
HU (1) | HUE028436T2 (xx) |
IL (1) | IL223888A (xx) |
MX (1) | MX2013000015A (xx) |
NZ (1) | NZ605841A (xx) |
PE (1) | PE20131106A1 (xx) |
PL (1) | PL2600846T3 (xx) |
PT (1) | PT2600846E (xx) |
RS (1) | RS54659B1 (xx) |
RU (1) | RU2589831C2 (xx) |
SI (1) | SI2600846T1 (xx) |
TW (1) | TWI526445B (xx) |
WO (1) | WO2012016695A2 (xx) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2600851T3 (en) | 2010-08-04 | 2018-06-25 | Gruenenthal Gmbh | PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN |
JP6276702B2 (ja) * | 2011-12-12 | 2018-02-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ−[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン塩酸塩の固体形態 |
US8912343B2 (en) * | 2011-12-12 | 2014-12-16 | Gruenenthal Gmbh | Solid forms of (1r,4r)-6′-fluoro-(N, N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and sulfuric acid |
US9320725B2 (en) * | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
US20130310435A1 (en) * | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
US9308196B2 (en) * | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
US9855286B2 (en) * | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
US8912226B2 (en) * | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
WO2014205261A1 (en) * | 2013-06-19 | 2014-12-24 | The Brigham And Women's Hospital, Inc. | Nanocomposite hydrogels |
JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および/または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
EP3324856A4 (en) | 2015-07-20 | 2019-03-27 | The Brigham and Women's Hospital, Inc. | SCHERVERDUNNENDE COMPOSITIONS AS INTRAVASCULAR EMBOLIC AGENT |
CN118286209A (zh) | 2016-02-29 | 2024-07-05 | 帕克治疗公司 | 西博帕多的滴定 |
EP4126881A1 (en) * | 2020-04-03 | 2023-02-08 | Vertex Pharmaceuticals Incorporated | Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) |
WO2024129782A1 (en) | 2022-12-12 | 2024-06-20 | Park Therapeutics, Inc. | Regimens and compositions useful for alleviating pain |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
-
2011
- 2011-08-04 HU HUE11745928A patent/HUE028436T2/hu unknown
- 2011-08-04 CA CA2804077A patent/CA2804077C/en not_active Expired - Fee Related
- 2011-08-04 WO PCT/EP2011/003900 patent/WO2012016695A2/en active Application Filing
- 2011-08-04 CN CN2011800382208A patent/CN103079548A/zh active Pending
- 2011-08-04 NZ NZ605841A patent/NZ605841A/en not_active IP Right Cessation
- 2011-08-04 AR ARP110102821A patent/AR082561A1/es not_active Application Discontinuation
- 2011-08-04 SI SI201130711T patent/SI2600846T1/sl unknown
- 2011-08-04 RU RU2013109138/15A patent/RU2589831C2/ru not_active IP Right Cessation
- 2011-08-04 PL PL11745928T patent/PL2600846T3/pl unknown
- 2011-08-04 AU AU2011287952A patent/AU2011287952B2/en not_active Ceased
- 2011-08-04 ES ES11745928.9T patent/ES2563735T3/es active Active
- 2011-08-04 TW TW100127868A patent/TWI526445B/zh not_active IP Right Cessation
- 2011-08-04 PT PT117459289T patent/PT2600846E/pt unknown
- 2011-08-04 JP JP2013522134A patent/JP6010534B2/ja not_active Expired - Fee Related
- 2011-08-04 KR KR1020137005293A patent/KR101882663B1/ko active IP Right Grant
- 2011-08-04 PE PE2013000193A patent/PE20131106A1/es active IP Right Grant
- 2011-08-04 BR BR112013002696A patent/BR112013002696A2/pt not_active IP Right Cessation
- 2011-08-04 EP EP11745928.9A patent/EP2600846B1/en active Active
- 2011-08-04 MX MX2013000015A patent/MX2013000015A/es active IP Right Grant
- 2011-08-04 DK DK11745928.9T patent/DK2600846T3/en active
- 2011-08-04 RS RS20160105A patent/RS54659B1/en unknown
-
2012
- 2012-12-19 CO CO12230455A patent/CO6640317A2/es not_active Application Discontinuation
- 2012-12-19 CL CL2012003583A patent/CL2012003583A1/es unknown
- 2012-12-25 IL IL223888A patent/IL223888A/en active IP Right Grant
-
2013
- 2013-02-04 EC ECSP13012424 patent/ECSP13012424A/es unknown
- 2013-08-16 HK HK13109593.7A patent/HK1183612A1/xx not_active IP Right Cessation
-
2015
- 2015-12-07 HR HRP20151337TT patent/HRP20151337T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1183612A1 (en) | Pharmaceutical dosage form comprising 6-fluoro-(n-methyl- or n,n-dimethyl- )-4-phenyl-4,9-dihydro-3h-spiro[cylohexane-1,1-pyrano[3,4,b]indol]-4- amine 6--(n-- nn-)-4--49--3h-[-11- [34b]]-4- | |
HK1183610A1 (en) | PHARMACEUTICAL DOSAGE FORM COMPRISING 6-FLUORO-(N-METHYL- OR N,N-DIMETHYL- g )-4-PHENYL-4,9-DIHYDRO-3H-SPIRO[CYCLOHEXANE-1,1-PYRANO[3,4,B]INDOL]-4- AMINE 6--(N-- NN-)-4--49--3H-[-11- [34B]]-4- | |
HK1259250A1 (zh) | 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的藥物製劑 | |
HRP20160579T1 (hr) | Spoj indola i njegova farmaceutska upotreba | |
ZA201006029B (en) | Pharmaceutical dosage form | |
DK2129595T3 (da) | Drikkevareingredienskapsel | |
GB2450753B (en) | New Pharmaceutical formulation | |
ZA201005015B (en) | Solid pharmaceutical dosage form | |
IL211400A0 (en) | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | |
ZA201104348B (en) | Pharmaceutical preparation | |
ZA200903858B (en) | Pharmaceutical dosage form | |
HK1137363A1 (en) | Novel dosage form | |
HU0800591D0 (en) | Stable pharmaceutical combination | |
GB0815972D0 (en) | Pharmaceutical preparation | |
HK1204943A1 (en) | Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a gabapentinoid (1r4r)-6--nn--4--49--3h-[-1 1-[34b]]-4- | |
ZA201300038B (en) | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl-or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine | |
IL215551A (en) | An indolite derivative, a pharmaceutical preparation containing it and its uses | |
GB0813031D0 (en) | Pharmaceutical formulations | |
GB0810217D0 (en) | Pharmaceutical formulations | |
GB0704123D0 (en) | Dosage form | |
GB0706970D0 (en) | Fermented ingredient | |
GB0705030D0 (en) | Pharmaceutical formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200729 |